Bengaluru, Mar 27 (TNT): Shreehas Tambe has been appointed Chief Executive Officer and Managing Director of Biocon Limited, effective April 1, 2026, the company announced on Friday.
The appointment follows approvals from the Board and the Nomination and Remuneration Committee. Kedar Upadhye has also been named Chief Financial Officer of the company.
Tambe will be the first CEO to lead the integrated Biocon following the consolidation of its biosimilars and generics businesses, aimed at strengthening scale and global competitiveness.
The move comes as part of the integration of Biocon Biologics as a wholly owned subsidiary, creating a unified corporate structure.
Executive Chairperson Kiran Mazumdar-Shaw said the integration marks a significant milestone in building a globally scaled biopharmaceutical enterprise, adding that Tambe’s leadership would drive the company’s next phase of growth.
She also acknowledged the contributions of outgoing CEO Siddharth Mittal, who will transition to another leadership role within the Biocon Group.
Tambe said he looks forward to leading the company at a pivotal time, focusing on expanding its global presence, strengthening its portfolio across biosimilars and generics, and advancing access to affordable healthcare solutions worldwide.
The integrated entity aims to expand its presence in key therapy areas including diabetes, obesity, oncology and immunology, supported by a portfolio of biosimilars, insulins, complex generics and GLP-1 therapies.
TNT RK
Leave a Reply